Head of Rare Neurology Development, Biogen
Appears in 1 story
Leading salanersen's clinical program
Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.
Updated Jun 4
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
